tbuckley/cabot-search huggingface dataset:
Characterization of Angiogenic Potential of Late Endothelial Progenitor Cells on Human Cord Blood and Bone Marrow
Authors: Eun-Sun Yoo, Jee-Young Ahn, KiHwan Kwon, Soo-Ah Oh, Moon-Young Choi, Yeung-Chul Mun, Kyoung-Eun Lee, Chu-Myong Seong
Journal: Blood (2008)
Gene expression in microdissected lung cancer samples from a large high-quality tissue collection reveals diagnostic and prognostic information that surpasses conventional histology
Authors: A. Niendorf, J. Von Frese, B. Haase, R. Geffers, K. Bendrat, T. Rhode, K. Schütze, J. Berger, U. Gatzemeier, D. Branscheid
Journal: Journal of Clinical Oncology (2004)

7029 Background: Most of today's post-genomic molecular methods require high quality frozen tissue specimens. With the focus on prognostic stratification, a long term follow-up is also required. Both is offered by an extensive lung tumor collection which has been established between 1988 and 2000. Since not all cases are suitable for high-end techniques such as gene expression analysis on microdissected tissues, the size of the initial tissue bank is of great importance. Methods: A total number of 622 cases (569 primary lung tumors and 53 metastases) including complete data follow-up was collected. For a subset (n=60) we performed mRNA expression analysis using Affymetrix U133A microarrays for bulk and microdissected material. Results: Survival depended on UICC tumor stages in accordance with the data of Mountain (1997) and von Rens (2000). Distinction between small cell and non-small cell lung cancers was the most significant histological classification. Otherwise, histology was not a stage-independent predictor of survival. However, there was a relative advantage for adenocarcinomas at early stages (IA and B) and for squamous cell carcinomas at more advanced stages. mRNA expression analysis allowed to identify known histological classes, and revealed a predictive set of genes for each histological subtype with respect to clinical outcome. Notably, laser microdissection of tumor tissue using the PALM-MicroBeam system allowed to
EFFICACY AND SAFETY OF PATIENTS TREATED WITH 48MM EVEROLIMUS ELUTING STENT AT 1 YEAR
Authors: Chong Keat Tan, Mohd Kamal Mohd Arshad, Hee Hwa Ho, Fahim H. Jafary, Jason K.K. Loh, Timothy Watson, Paul J.L. Ong
Journal: Journal of the American College of Cardiology (2017)
IMPACT OF PERIPROCEDURAL MYOCARDIAL INFARCTION IN CONTEMPORARY PCI: POOLED PATIENT-LEVEL DATA FROM THE CHAMPION TRIALS
Authors: Muthiah Vaduganathan, Robert Harrington, Gregg Stone, Philippe Steg, C. Michael Gibson, Christian Hamm, Matthew Price, Efthymios Deliargyris, Jayne Prats, Kenneth Mahaffey, Harvey White, Deepak Bhatt
Journal: Journal of the American College of Cardiology (2017)
Comorbidity and other predictors of survival in veterans with metastatic renal cell carcinoma (RCC).
Authors: Michael Cho, Trent P Wang, Melanie L. Gonzalez, Victor T Chang, Fengming Zhong, Shanthi Srinivas, Barbara Crump, Emma R Paz-Querubin, Monica McPherson, Marvin Blumenfrucht, Basil Kasimis
Journal: Journal of Clinical Oncology (2013)

e15561 Background: Comorbidity as a prognostic marker has been reported in several solid tumors. We examined whether co-morbidity indices predict survival in Veterans with metastatic renal cell carcinoma (RCC) who were treated with signal transduction inhibitors. Methods: In an IRB-approved protocol, we reviewed the records of patients (Pts) diagnosed with RCC at a VA Medical Center from 1/1/2000 to 12/31/2011. Age, ECOG Performance Status (ECOG PS), Hemoglobin (Hgb), Albumin (Alb), Corrected Calcium (CCa), history of Nephrectomy, and histology (clear cell (CC) vs. non clear cell (NCC)) were abstracted. Co-morbidity was assessed with Charlson Comorbidity Index (CCI), and the Kaplan-Feinstein Index (KFI). We developed a survival model with age, ECOG PS, Hgb, Alb, CCa, history of nephrectomy, and histology. Co-morbidity indices were tested by determining if they were independent predictors of survival after inclusion in this model. Cox regression analyses were performed with SAS V9.2. Results: There were 24 Pts;6 (25%) are alive. The Median (M) age when seen at VA was 64 years (54-85). The M Hgb level was 12.1g/dL (6.7-16.5), Alb was 4.1g/dL (2.8-5.0), and CCa was 9.19mg/dL (7.9-12.5). The M CCI was 4.2 (1.4-12.0) and KFI was 2.0 (1-3). The M Survival was 823 days (24-3482). 17(68%) pts had clear cell carcinoma and 18(72%) had nephrectomies Median ECOG PS was one range(0-4). The median number of treatments was 2, range 1-7. Results of univariate analyses with co-morbidity indices were significant for age (p &lt; ,029) and history of nephrectomy p&lt; .068). There were no multivariate predictors of survival. Conclusions: In the univariate analysis, ECOG PS as well as Nephrectomy status were significant predictors for M survival. CCI and KFI did not predict M survival. In distinction to other solid tumor histologies where chemotherapy is used, KFI and CCI in RCC may not be associated with overall survival due to either RCC histology or use of signal transduction inhibitors as treatment. Confirmatory studies should be done in larger populations. This was supported by the New Jersey Commission for Cancer Research.
Correlation between poly (ADP-ribose) polymerase (PARP) and phospho-p65 expression in human breast cancer.
Authors: Lisa Caroline Klepczyk, Shi Wei, Jason D. Brazelton, Kimberly Sue Keene, James A. Bonner, Albert F. LoBuglio, Andres Forero, William E. Grizzle, Eddy Shih-Hsin Yang
Journal: Journal of Clinical Oncology (2013)

623 Background: Despite the efficacy of targeted agents in patients with HER2+ breast cancer, resistance often develops necessitating novel treatment strategies. Poly (ADP-ribose) polymerase inhibitors (PARPi) are known to target tumors with aberrant DNA repair. We previously reported sensitivity of HER2+ breast cancer cells to PARPi independent of a DNA repair deficiency but rather due to attenuation of NF-kB signaling. In this study, we investigated the expression of PARP and the active NF-kB subunit phospho-p65, indicators of activity for these pathways, in human HER2+ breast tumors and compared to HER2- tumors. Methods: Patients with breast cancer treated at the University of Alabama at Birmingham between the years 1999 and 2012 were identified. Formalin-fixed, paraffin-embedded tissue blocks were stained for PARP and phospho-p65 and evaluated independently by two blinded physicians, including a board-certified pathologist. An H-score was calculated by multiplying the percent of tumor cells with staining intensity of 0, 1, 2, and 3 and subsequently adding these together for a final score of 0-300. Nuclear and cystosolic staining were scored separately for both proteins. Results: Forty-six HER2+ and 38 HER2- patients with available tissue were identified; however, only 41 HER2+ and 32 HER2- cases had tumoral tissue at the time of analysis. PARP and phospho-p65 were found to be almost exclusively nuclear in both groups. The mean nuclear PARP score was 122.3 in HER2+ cases compared to 61.6 in HER2- cases (p value &lt;0.0001). Mean nuclear phospho-p65 scores were 89.0 and 59.4 in HER2+ and HER2- groups, respectively (p value 0.0008). Additionally, a significantly positive correlation was observed between PARP and phospho-p65 levels. Conclusions: Our study suggests that HER2+ breast cancers have elevated PARP and NF-kB activity compared to HER2- cancers. Furthermore, a direct correlation between PARP and phospho-p65 levels was found. When combined with our previously published preclinical findings, the current research supports the potential clinical utility of PARPi in patients with this aggressive form of breast cancer.
Improved Survival with Adjuvant Donor Lymphocyte Transfusions Following Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-Risk AML.
Authors: Michael Schleuning, Christoph Schmid, Christian Koenecke, Bernd Hertenstein, Herrad Baurmann, Rainer Schwerdtfeger, Hans-Jochem Kolb
Journal: Blood (2006)
PRO-ATHEROGENIC PROPERTIES OF PLASMA FROM PATIENTS WITH TYPE 1 DIABETES MELLITUS: EFFECTS ON MACROPHAGE LIPID HANDLING
Authors: Joshua R. DeLeon, Jorge Mejia Corletto, Siham Accacha, Iryna Voloshyna, Nicolle Siegart, Lora Kasselman, Mariano Castro Magana, Allison Reiss
Journal: Journal of the American College of Cardiology (2017)
RELATIONSHIP BETWEEN FRACTIONAL FLOW RESERVE (FFR) AND CORONARY FLOW RESERVE (CFR) BY PET IN IDENTIFYING CORONARY STENOSIS CAUSING MYOCARDIAL ISCHEMIA
Authors: Giulia Arena, Alberto Morello, Antonello D'Andrea, Bernardino Tuccillo, Francesco Punzo, Fortunato Scotto Di Uccio, Wanda Acampa, Letizia Spinelli, Roberta Assante, Emilia Zampella, Giovanni Cimmino, Alberto Cuocolo, Paolo Golino
Journal: Journal of the American College of Cardiology (2017)
Use of germ-line variants in the WNT/β-CATENIN pathway to predict tumor recurrence in adjuvant colon cancer.
Authors: Peter M.D. Wilson, David Páez, Armin Gerger, Wu Zhang, Dongyun Yang, Melissa Janae Labonte, Leonor Benhaim, Pierre Oliver Bohanes, Yan Ning, Takeru Wakatsuki, Fotios Loupakis, Heinz-Josef Lenz
Journal: Journal of Clinical Oncology (2012)

e14034 Background: The Wnt/β-catenin signaling plays a central role in the development and progression of most colon cancers. Germline variants in Wnt/β-catenin pathway genes may result in altered gene function and/or activity, thereby causing inter-individual differences in relation to tumor recurrence capacity and chemoresistance. We investigated germline polymorphisms in a comprehensive panel of Wnt/β-catenin pathway genes to predict time to tumor recurrence (TTR) in patients with stage III and high-risk stage II colon cancer. Methods: A total of 234 patients treated with 5-fluorouracil-based chemotherapy at the University of Southern California were included in this study. Whole blood samples were analyzed for putative functional germline polymorphisms in SFRP3, SFRP4, DKK2, DKK3, Axin2, APC, TCF7L2, WNT5B, CXXC4 genes by PCR-RFLP or direct DNA-sequencing. We also included NOTCH2 and GLI1 variants which belong to the Notch and Hedgehog pathways respectively. Results: The minor allele of WNT5B rs2010851 T&gt;G was significantly associated with a shorter TTR (4.9vs10.7 years; HR: 2.48; 95%CI, (0.96, 6.38); p=0.044) in high-risk stage II colon cancer patients. This result remained significant in the multivariate Cox regression analysis. Conclusions: Despite the importance of Wnt/β-catenin pathway in the development of cancer, only the WNT5B germline variant rs2010851 was significantly identified as a stage-dependent prognostic marker for colon cancer patients after 5-fluorouracil-based adjuvant therapy.
ATRIAL FIBRILLATION LINK TO EXCESS MORTALITY IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION: LINKED TO RAPID VENTRICULAR RESPONSE OR INDEPENDENT PROGNOSTIC MARKER?
Authors: Giovanni Benfari, Clemence Antoine, Wayne Miller, Hector Michelena, Vuyisile Nkomo, Maurice Sarano
Journal: Journal of the American College of Cardiology (2017)
Clinical Results of a −80°C Simplified Cryo-Preservation Method.
Authors: Jose R. Borbolla Escoboza, Manuel A. Lopez-Hernandez, Marcos E. Garza, Enrique Baez, Elvira Trueba, Roberto Hernandez, Jose E. DeDiego-FloresChapa, Severiano Baltazar, Martha Alvarado, Gerardo Villareal, Mauricio C. Gonzalez-Avante, Rosa E. De Leon, Jose L. Cedillo, Jason A. Penniecook, Yara E. Tovar, Maria I. Leon, Cecilia Ramirez-Assad
Journal: Blood (2004)
SYSTEMIC ARTERIAL PULSATILITY INDEX (SAPI) PREDICTS ADVERSE OUTCOMES IN ADVANCED HEART FAILURE PATIENTS
Authors: Sula Mazimba, Timothy Welch, Peter McCullough, Khadijah Breathett, Jose Tallaj, James Bergin, Jamie Kennedy, Lavone Smith, Mohammad Abuannadi, Kenneth Bilchick
Journal: Journal of the American College of Cardiology (2017)
UNDERTREATMENT OF FEMALE PATIENTS IN LIPID-LOWERING FOR SECONDARY PREVENTION IN EUROPE, CANADA, SOUTH-AFRICA, MIDDLE EAST AND CHINA: RESULTS OF THE DYSLIPIDEMIA INTERNATIONAL STUDY (DYSIS)
Authors: Anselm K. Gitt, Dominik Lautsch, Martin Horack, Philippe Brudi, Larry Liu, Jean Ferrières
Journal: Journal of the American College of Cardiology (2017)
RACIAL DIFFERENCES IN PATIENTS REFERRED FOR RIGHT HEART CATHETERIZATION AND RISK OF PULMONARY HYPERTENSION
Authors: Bin Yang, Tufik R. Assad, Reid D'Amico, Stephen J. Halliday, Meng Xu, Eric Farber-Eger, Quinn S. Wells, Evan L. Brittain
Journal: Journal of the American College of Cardiology (2017)
Beyond metastatic renal cell carcinoma (mRCC) clinical trials: Targeted therapy use and overall survival in community oncology clinics.
Authors: Michael Roger Harrison, Daniel J. George, Mark S. Walker, Lori L. Hudson, Connie Chen, Beata Korytowsky, Edward J. Stepanski, Amy Pickar Abernethy
Journal: Journal of Clinical Oncology (2012)

e15061 Background: Targeted therapies are now the standard of care for mRCC with use and expected outcomes defined by clinical trials. What are "real world" patterns of use and survival outcomes in mRCC patients (pts) treated in community oncology (COMM) settings? Methods: We reviewed a retrospective registry of adult mRCC pts from 11 COMM oncology practices, diagnosed since 1/2007 and not enrolled in a trial. Demographics, disease characteristics, treatment patterns and outcomes were recorded from the EMR and supplemented with chart abstraction.Pts were grouped by treatment sequence reflecting up to 3 exposures based on drug mechanism of action (VEGFR TKI [TKI] or mTOR inhibitor [mTOR]). Other pts received a non-TKI, non-mTOR therapy in the 1st three exposures (e.g., bevacizumab, cytokines, combinations, etc.). No Therapy pts received no systemic therapy as of data analysis. Survival analyses included Kaplan-Meier methods and Cox regression. Results: 255 patient/disease characteristics included: age 65±11 yrs; 68% male; 71% Caucasian; 62% clear cell histology (25% unknown); 1.6 ±0.9 metastatic sites. MSKCC risk was: 28% good, 63% intermediate, 10% poor. Median overall survival (OS) was 12.1 mo (95% CI: 8.7-15.4); median OS by sequence was: No Therapy (n=38; 3.7), mTOR (n=28; 5.2), TKI (n=79; 8.7), mTOR/TKI (n=10; 9.3), TKI/mTOR (n=32; 13.7), TKI/TKI (n=24; 20.7), Other (n=20; 22.5), TKI/mTOR/TKI (N=14; 29.8), TKI/TKI/mTOR (N=10; 33.1). Cox regression identified subgroups with differential outcomes. After significant covariates were controlled, compared with No Therapy, all regimens with TKI as 1st exposure had hazard ratios (HR) &lt;1.0 (range=0.14 – 0.51; all p values ≤ 0.02). Other treatment had HR=0.31 (P=0.001), but when mTOR was the only treatment HR=1.04 (p=0.88). MSKCC scores of intermediate (HR=2.4) or poor (HR=4.5) were a significant risk (p&lt;0.001). Conclusions: Only pts treated with two TKI exposures (≥20.7 mo) approached the best OS seen in trials (26 mo). For mTOR only, 1st line treatment in sicker patients, OS (5.2 mo) was shorter than trials (11 mo). Outcome differences between trial and community practice settings offer insights into opportunities to optimize care.
CLINICAL, ANGIOGRAPHIC AND PROCEDURAL CORRELATES OF ABSORB SCAFFOLD THROMBOSIS: A MATCHED MULTICENTER REGISTRY ANALYSIS
Authors: Stephen G. Ellis, Tommaso Gori, Giuseppe Steffenino, Dean Kereiakes, Gregg Stone, Holger Nef, Salvatore Brugaletta, Luca Testa, Alexandre Abizaid, Takeshi Kimura, Corrado Tamburino, Robert-Jon van Guens, Patrick Serruys, Maurizio Menichelli, Bernardo Cortese, Run-Lin Gao
Journal: Journal of the American College of Cardiology (2017)
EKG ABNORMALITIES DISTRIBUTION BETWEEN COMPETITIVE ATHLETES, NON COMPETITIVE ATHLETES AND NON ATHLETES IN A POPULATION OF 12,000 YOUNG ITALIAN STUDENTS
Authors: Antonio Fusto, Paola Scarparo, Alessandra Cinque, Francesco Adamo, Nicolo’ Salvi, Mariateresa Pucci, Gianluca Agnes, Pasqualina Bruno, Maria Chiara Gatto, Ilaria Mancini, Giammarco Schiaffini, Maria Giovanna Vassallo, Alessandra D'Ambrosi, Danilo Alunni Fegatelli, Annarita Vestri, Massimo Mancone, Francesco Fedele
Journal: Journal of the American College of Cardiology (2017)
LEFT ATRIAL APPENDAGE FLOW VELOCITY TO PREDICT PERSISTENT LEFT ATRIAL APPENDAGE ISOLATION
Authors: Carola Gianni, Sanghamitra Mohanty, Chintan Trivedi, Rong Bai, Amin Al-Ahmad, John Burkhardt, G. Gallinghouse, Patrick Hranitzky, Rodney Horton, Javier Sanchez, Luigi Di Biase, Andrea Natale
Journal: Journal of the American College of Cardiology (2017)
Rivipansel: A Small Pan-Selectin Antagonist Improves Cerebral Perfusion and Inhibits Leukocyte Adhesion and in Murine Sickle Cell Disease Model
Authors: Reema Jasuja, Georgette Suidan, Sunita Patel Hett, Kunal Desai, Kevin X Le, Elizabeth Parks, Robert Bell, John E. Murphy, Debra D Pittman
Journal: Blood (2016)
Wavelet-based prognostic model with comparative genomic hybridization (CGH) data in patients with hepatocellular carcinoma (HCC)
Authors: B. C. Zee, J. Lee, N. Wong, W. Yeo, P. Lai, L. Chan, P. Hui, H. Wong, K. Lam, W. Ho, A. T. Chan
Journal: Journal of Clinical Oncology (2006)

20026 Background: In order to obtain a good prognostic model for HCC, clinical data alone may not be adequate. DNA microarray technology has enabled quantification of thousands of genes in a single assay but it has the inborn drawback of high background noise. In order to deal with the problem of information overflow, we developed multivariate dependencies approach using CGH to guide the initial modeling process. This approach takes into account the multivariate nature and potential interaction among the genes during the prognostic modeling process. Methods: The study includes 165 patients with CGH data containing 858 regions/bands. The clinical outcome is survival at 1.72 years. Potential prognostic factors include CGH regions, albumin, ALT, bilirubin, AFP, ascites, alkaline phosphatase (ALP), tumor size, and encephalopathy. We used a blocked wavelet-shrinkage principal component analysis (BWSPCA) to reduce the dimension of CGH data with respect to clinical outcome and followed by logistic regression. We compared the BWSPCA with PCA alone, supervised PCA (Bair et al. 2004), and supervised BWSPCA. Results: Among the 165 patients, 133 (80%) were male, average age of 54.8 years, 78 (47%) stage I-II and 75 (45%) ECOG 0–2. PCA alone and supervised PCA models failed to identify significant CGH regions. BWSPCA model includes tumor size (p = 0.005), albumin (p = 0.047), ALP (p = 0.025), Chr.6q25.1 (p = 0.031), Chr.12q24.32 (p = 0.012), Chr.Xq28 (p = 0.035). Supervised BWSPCA approach includes tumor size (p = 0.016), ALP (p = 0.002), Chr.12q24.11 (p = 0.047). The area under the receiver operating curve (ROC) for the BWSPCA model was 0.78 with a sensitivity and specificity about 0.8 and 0.6 respectively. Conclusions: PCA alone is not effective in identifying CGH regions as prognostic factors. Supervised learning approach did not improve the results. The BWSPCA method identified a number of significant CGH regions associated with survival outcome for HCC patients. These results would be verified in future study. This method will be extended and applied to develop prognostic models using both CGH and DNA microarray data. Acknowledgement: This study is funded by the Research Grant Council of Hong Kong #CUHK4469/03M. No significant financial relationships to disclose.
COMBINED HEART-KIDNEY TRANSPLANTATION IN A PATIENT WITH HUMAN IMMUNODEFICIENCY VIRUS
Authors: Sohaib Tariq, Anoshia Raza, Roshni Narurkar, Wilbert Aronow, Ali Ahmed, Julio Panza, Howard Cooper, Gregg Lanier, Alan Gass, Chhaya Aggarwal
Journal: Journal of the American College of Cardiology (2017)
Current outcomes and predictors of treatment failure in patients with surgical site infection after elective colorectal surgery. A multicentre prospective cohort study
Authors: Aina Gomila, Josep Ma Badia, Jordi Carratalà, Xavier Serra-Aracil, Evelyn Shaw, Vicens Diaz-Brito, Antoni Castro, Elena Espejo, Carmen Nicolás, Marta Piriz, Montserrat Brugués, Josefina Obradors, Ana Lérida, Jordi Cuquet, Enric Limón, Francesc Gudiol, Miquel Pujol
Journal: Journal of Infection (2017)
Gilteritinib (ASP2215), a Novel FLT3/AXL Inhibitor: Preclinical Evaluation in Combination with Azacitidine in Acute Myeloid Leukemia
Authors: Yoko Ueno, Masamichi Mori, Yoshiteru Kamiyama, Naoki Kaneko, Eriko Isshiki, Masahiro Takeuchi
Journal: Blood (2016)
FACTORS ASSOCIATED WITH RAPID PROGRESSION OF AORTIC STENOSIS IN PATIENTS WITH BICUSPID AORTIC VALVE: A SINGLE CENTER RETROSPECTIVE STUDY
Authors: Amartya Kundu, Renee Dallasen, Adedotun Ogunsua, Suvasini Lakshmanan, Nikhil Shah, John Dickey, Bryon Gentile, Matthew Parker, Linda Pape
Journal: Journal of the American College of Cardiology (2017)
IMPACT OF PREPROCEDURAL THROMBOCYTOPENIA ON SAFETY OF PERFORMING PERCUTANEOUS CORONARY INTERVENTION IN CANCER PATIENTS
Authors: Dana Giza, Juan Lopez-Mattei, Jean-Bernard Durand, Ezequiel D. Muñoz Gonzalez, Syed Yusuf, Elie Mouhayar, Kostas Marmagiolis, Cezar Iliescu
Journal: Journal of the American College of Cardiology (2017)
Effect of gefitinib on the systemic disposition of intravenous irinotecan (IRN) in pediatric patients with refractory solid tumors
Authors: L. C. Iacono, W. L. Furman, K. R. Crews, J. C. Panetta, B. B. Freeman, N. C. Daw, C. F. Stewart
Journal: Journal of Clinical Oncology (2004)

2011 Background: We are conducting a Phase I and pharmacokinetic (PK) study of gefitinib and IRN in children with refractory solid tumors with the objective to evaluate the effect of gefitinib on IRN and SN-38 disposition. Methods: Patients received IV IRN (15 mg/m2/d) daily x 5 days for two consecutive weeks every 21 days, and oral gefitinib (112.5 or 150 mg/m2/d) continuously beginning on day 2 of IRN therapy. Serial plasma samples for IRN PK were collected during course 1 on day 1 (prior to gefitinib administration) and on day 8 (after 7 days of gefitinib), and during course 2 on day 1 of IRN (after 21 days of gefitinib). Serial plasma samples were collected during course 1 on day 8 for gefitinib PK. IRN, SN-38 and SN-38 glucuronide lactone concentrations were measured using a validated HPLC assay, and gefitinib concentrations were measured using a novel HPLC MS/MS method. Pharmacokinetic analysis of IRN and its metabolites was performed using maximum a posteriori (Bayesian) estimation with priors from previously reported patients. Results: To date, 6 children have participated in IRN PK studies with (n = 9 studies) and without (n = 7 studies) gefitinib. Steady-state gefitinib concentrations approximated values needed for inhibition of the camptothecin-analog transporter, BCRP, and were comparable to those observed in other children treated with gefitinib alone. Concurrent administration of gefitinib reduced the median IRN clearance from 34.4 L/hr/m2 (range, 9.4 – 55.0) to 31.8 L/hr/m2 (range, 8.1 – 46.9; 8% reduction; p<0.05) and increased the median SN-38 AUC from 67.8 ng*hr/mL (range, 27.2 – 240) to 91.4 ng*hr/mL (range, 44.5 – 222; 26% increase; p=0.06). Conclusions: These data suggest that combining gefitinib with IRN results in decreased IRN clearance, which may result in an increased systemic exposure to SN-38, the active metabolite. The mechanism for this interaction is currently being investigated. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca; ALSAC; NIH
CORONARY MICROVASCULAR DYSFUNCTION IS RELATED TO LEFT VENTRICULAR CONCENTRIC REMODELING AND DIASTOLIC DYSFUNCTION: FROM THE WISE-CVD STUDY
Authors: Seong-Mi Park, Janet Wei, Louise Thomson, Daniel Berman, Eileen Handberg, John Petersen, Carl Pepine, C. Noel Bairey Merz
Journal: Journal of the American College of Cardiology (2017)
DIAGNOSTIC PERFORMANCE OF HYBRID ASSESSMENT WITH STRESS ONLY MYOCARDIAL PERFUSION SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY USING SEMICONDUCTOR GAMMA CAMERA AND REST MYOCARDIAL SCAR FINDINGS OBTAINED FROM 320 DETECTOR ROW COMPUTED TOMOGRAPHY
Authors: Yasuyuki Suzuki, Keiichiro Kuronuma, Ayano Makita, Yusuke Hori, Shunichi Yoda, Naoya Matsumoto, Atsushi Hirayama
Journal: Journal of the American College of Cardiology (2017)